287 related articles for article (PubMed ID: 38308727)
1. Etanercept in Axial Spondyloarthritis, Psoriatic Arthritis, and Plaque Psoriasis: Real-World Outcome Data from German Non-interventional Study ADEQUATE.
Feist E; Baraliakos X; Behrens F; Thaçi D; Plenske A; Klaus P; Meng T
Rheumatol Ther; 2024 Apr; 11(2):331-348. PubMed ID: 38308727
[TBL] [Abstract][Full Text] [Related]
2. Long-term safety of Ixekizumab in adults with psoriasis, psoriatic arthritis, or axial spondyloarthritis: a post-hoc analysis of final safety data from 25 randomized clinical trials.
Deodhar A; Blauvelt A; Lebwohl M; Feely M; Kronbergs A; Eberhart N; Zhu D; Inman E; Grace E; Holzkaemper T; Rahman P; Marzo-Ortega H; Papp KA; Merola JF; Gottlieb AB; Schwartzman S
Arthritis Res Ther; 2024 Feb; 26(1):49. PubMed ID: 38347650
[TBL] [Abstract][Full Text] [Related]
3. Effectiveness of Etanercept in Rheumatoid Arthritis: Real-World Data from the German Non-interventional Study ADEQUATE with Focus on Treat-to-Target and Patient-Reported Outcomes.
Feist E; Baraliakos X; Behrens F; Thaçi D; Klopsch T; Plenske A; Blindzellner LK; Klaus P; Meng T; Löschmann PA
Rheumatol Ther; 2022 Apr; 9(2):621-635. PubMed ID: 35113363
[TBL] [Abstract][Full Text] [Related]
4. Safety Profile of Upadacitinib up to 5 Years in Psoriatic Arthritis, Ankylosing Spondylitis, and Non-radiographic Axial Spondyloarthritis: An Integrated Analysis of Clinical Trials.
Burmester GR; Stigler J; Rubbert-Roth A; Tanaka Y; Azevedo VF; Coombs D; Lagunes I; Lippe R; Wung P; Gensler LS
Rheumatol Ther; 2024 Jun; 11(3):737-753. PubMed ID: 38683479
[TBL] [Abstract][Full Text] [Related]
5. Treatment Patterns and Healthcare Resource Utilization Among Newly Diagnosed Psoriasis, Psoriatic Arthritis, Axial Spondyloarthritis, and Hidradenitis Suppurativa Patients with Past Diagnosis of an Inflammatory Condition: A Retrospective Cohort Analysis of Claims Data in the United States.
Hopson S; Gibbs LR; Syed S; Low R; McClung L; Beaty S
Adv Ther; 2023 Oct; 40(10):4358-4376. PubMed ID: 37486558
[TBL] [Abstract][Full Text] [Related]
6. Characterisation of patients with axial psoriatic arthritis and patients with axial spondyloarthritis and concomitant psoriasis in the SCQM registry.
Ciurea A; Götschi A; Kissling S; Bernatschek A; Bürki K; Exer P; Nissen MJ; Möller B; Scherer A; Micheroli R
RMD Open; 2023 Jun; 9(2):. PubMed ID: 37277211
[TBL] [Abstract][Full Text] [Related]
7. Comparison of patients with axial PsA and patients with axSpA and concomitant psoriasis: an analysis of the German register RABBIT-SpA.
Regierer AC; Weiß A; Proft F; Baraliakos X; Behrens F; Poddubnyy D; Schett G; Lorenz HM; Worsch M; Strangfeld A
RMD Open; 2023 Mar; 9(1):. PubMed ID: 36898762
[TBL] [Abstract][Full Text] [Related]
8. Characteristics associated with poor COVID-19 outcomes in people with psoriasis, psoriatic arthritis and axial spondyloarthritis: data from the COVID-19 PsoProtect and Global Rheumatology Alliance physician-reported registries.
Machado PM; Schäfer M; Mahil SK; Liew J; Gossec L; Dand N; Pfeil A; Strangfeld A; Regierer AC; Fautrel B; Alonso CG; Saad CGS; Griffiths CEM; Lomater C; Miceli-Richard C; Wendling D; Alpizar Rodriguez D; Wiek D; Mateus EF; Sirotich E; Soriano ER; Ribeiro FM; Omura F; Rajão Martins F; Santos H; Dau J; Barker JN; Hausmann J; Hyrich KL; Gensler L; Silva L; Jacobsohn L; Carmona L; Pinheiro MM; Zelaya MD; Severina MLÁ; Yates M; Dubreuil M; Gore-Massy M; Romeo N; Haroon N; Sufka P; Grainger R; Hasseli R; Lawson-Tovey S; Bhana S; Pham T; Olofsson T; Bautista-Molano W; Wallace ZS; Yiu ZZN; Yazdany J; Robinson PC; Smith CH
Ann Rheum Dis; 2023 May; 82(5):698-709. PubMed ID: 36787993
[TBL] [Abstract][Full Text] [Related]
9. Etanercept is Effective and Halts Radiographic Progression in Rheumatoid Arthritis and Psoriatic Arthritis: Final Results from a German Non-interventional Study (PRERA).
Wassenberg S; Rau R; Klopsch T; Plenske A; Jobst J; Klaus P; Meng T; Löschmann PA
Rheumatol Ther; 2023 Feb; 10(1):117-133. PubMed ID: 36251174
[TBL] [Abstract][Full Text] [Related]
10. Clinical Burden of Concomitant Joint Disease in Psoriasis: A US-Linked Claims and Electronic Health Records Database Analysis.
Skornicki M; Prince P; Suruki R; Lee E; Louder A
Adv Ther; 2021 May; 38(5):2458-2471. PubMed ID: 33818686
[TBL] [Abstract][Full Text] [Related]
11. High disease relapse after bDMARD spacing in psoriatic arthritis compared to rheumatoid arthritis and axial spondyloarthritis patients: real-life data from BIOPURE registry.
Fornaro M; Righetti G; Abbruzzese A; Lopalco G; Cacciapaglia F; Anelli MG; Venerito V; Iannone F
Clin Rheumatol; 2021 Sep; 40(9):3659-3665. PubMed ID: 33864158
[TBL] [Abstract][Full Text] [Related]
12. Using natural language processing to explore characteristics and management of patients with axial spondyloarthritis and psoriatic arthritis treated under real-world conditions in Spain: SpAINET study.
Benavent D; Muñoz-Fernández S; De la Morena I; Fernández-Nebro A; Marín-Corral J; Castillo Rosa E; Taberna M; Sanabra C; Sastre C;
Ther Adv Musculoskelet Dis; 2023; 15():1759720X231220818. PubMed ID: 38146537
[TBL] [Abstract][Full Text] [Related]
13. Drug survival of biologics and novel immunomodulators for rheumatoid arthritis, axial spondyloarthritis, psoriatic arthritis, and psoriasis - A nationwide cohort study from the DANBIO and DERMBIO registries.
Egeberg A; Rosenø NAL; Aagaard D; Lørup EH; Nielsen ML; Nymand L; Kristensen LE; Thyssen JP; Thomsen SF; Cordtz RL; Loft N; Skov L; Bryld LE; Rasmussen MK; Højgaard P; Kristensen S; Dreyer L
Semin Arthritis Rheum; 2022 Apr; 53():151979. PubMed ID: 35183936
[TBL] [Abstract][Full Text] [Related]
14. Real-World Effectiveness and Safety of SDZ ETN, an Etanercept Biosimilar, in Patients with Rheumatic Diseases: Final Results from Multi-Country COMPACT Study.
Schmalzing M; Kellner H; Askari A; De Toro Santos J; Vazquez Perez-Coleman JC; Foti R; Jeka S; Haraoui B; Allanore Y; Peichl P; Oehri M; Rahman M; Furlan F; Romero E; Hachaichi S; Both C; Brueckmann I; Sheeran T
Adv Ther; 2024 Jan; 41(1):315-330. PubMed ID: 37950790
[TBL] [Abstract][Full Text] [Related]
15. Patient-reported outcomes in axial spondyloarthritis and psoriatic arthritis patients treated with secukinumab for 24 months in daily clinical practice.
Christiansen SN; Horskjær Rasmussen S; Pons M; Michelsen B; Glintborg B; Gudbjornsson B; Grondal G; Vencovsky J; Loft AG; Rotar Z; Pirkmajer KP; Nissen MJ; Baranová J; Macfarlane GJ; Jones GT; Iannone F; Caporali R; Laas K; Vorobjov S; Giuseppe DD; Olofsson T; Provan SA; Fagerli KM; Castrejon I; Otero-Varela L; van de Sande M; van der Horst-Bruinsma I; Nordström D; Kuusalo L; Bernardes M; Hetland ML; Østergaard M; Midtbøll Ørnbjerg L
Semin Arthritis Rheum; 2024 Apr; 65():152388. PubMed ID: 38301349
[TBL] [Abstract][Full Text] [Related]
16. Real-world effectiveness of golimumab in adult patients with rheumatoid arthritis, psoriatic arthritis, and axial spondyloarthritis and an inadequate response to initial TNFi therapy in Greece: the GO-BEYOND prospective, observational study.
Athanassiou P; Psaltis D; Georgiadis A; Katsifis G; Theodoridou A; Gazi S; Sidiropoulos P; Tektonidou MG; Bounas A; Kandyli A; Vounotrypidis P; Sakellariou GT; Vassilopoulos D; Huang Z; Petrikkou E; Boumpas D
Rheumatol Int; 2023 Oct; 43(10):1871-1883. PubMed ID: 37402886
[TBL] [Abstract][Full Text] [Related]
17. Real-world evidence for secukinumab in UK patients with psoriatic arthritis or radiographic axial spondyloarthritis: interim 2-year analysis from SERENA.
Gaffney K; Gullick N; MacKay K; Patel Y; Sengupta R; Sheeran T; Hemmings L; Pamies P
Rheumatol Adv Pract; 2023; 7(3):rkad055. PubMed ID: 37663578
[TBL] [Abstract][Full Text] [Related]
18. Treatment with Upadacitinib in Active Psoriatic Arthritis: Efficacy and Safety Data of the First 192 Patients from the UPJOINT Study, a Multicentre, Observational Study in Clinical Practice.
Werner SG; Baraliakos X; Reckert S; Bohl-Bühler M; Laliberté MC; Girard T; Jeromin K; Baschuk N; Fritz B; Bessette L; Hueber AJ
Rheumatol Ther; 2023 Dec; 10(6):1503-1518. PubMed ID: 37695506
[TBL] [Abstract][Full Text] [Related]
19. Depressive symptoms are associated with fatigue, poorer functional status and less engagement in sports in axSpA and PsA: an analysis from the RABBIT-SpA cohort.
Reich A; Weiß A; Lindner L; Baraliakos X; Poddubnyy D; Zinke S; Stille C; Strangfeld A; Regierer AC
Arthritis Res Ther; 2023 Aug; 25(1):136. PubMed ID: 37533077
[TBL] [Abstract][Full Text] [Related]
20. The PROPER Study: A 48-Week, Pan-European, Real-World Study of Biosimilar SB5 Following Transition from Reference Adalimumab in Patients with Immune-Mediated Inflammatory Disease.
Müller-Ladner U; Dignass A; Gaffney K; Jadon D; Matucci-Cerinic M; Lobaton T; Carron P; Gisbert JP; Pande I; Utzinger M; Addison J
BioDrugs; 2023 Nov; 37(6):873-889. PubMed ID: 37632666
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
